Original news and analysis on international IP policy
Reposted from Afro-IP and infojustice.org: A report entitled 'Copyright policy and the right to science and culture' authored by the UN Special Rapporteur in the field of cultural rights, Farida Shaheed, has been released, writes Prof. Carolyn Ncube.
The biotechnology industry is closely watching developments in the United States that could impact the industry in 2015. These include the regulatory framework for biosimilars, possible patent legislation, post-grant review procedure, and the consequences of the recent Supreme Court ruling banning the patenting of human genes. Hans Sauer, Deputy General Counsel for Intellectual Property at the Biotechnology Industry Organization (BIO), recently spoke with Intellectual Property Watch’s Catherine Saez. Sauer was asked to lay out the main developments to watch in the coming year.
The Union for Affordable Cancer Treatment has sent a letter to the author of a much-noted Tufts University (US) study that found high development costs for medicines, with copies to the university administration. The letter requests transparency on the funding of the study and the press conference announcing the results, as well as copies of the study itself, which the group says was not made public, along with details to justify the result.
The World Health Organization Executive Board this week recommended the extension of an important strategy and plan of action on health, IP and innovation. It also set out steps to resolve questions over evaluation and review of the strategy and plan of action before the annual World Health Assembly in May.
In search of sustainable innovation models for cures for diseases affecting primarily developing countries, with the Ebola epidemic as a new reminder of the necessity and urgency of the matter, the World Health Organization had tasked an expert working group with the search for solutions. Last week, the WHO Executive Board took note of the progress made so far.
It is no secret that the United States has been scaling up pressure on India to adopt intellectual property measures similar to those common in the United States and the European Union. But to what extent does India’s new government led by the business-friendly Narendra Modi see eye to eye with US official position? Can India, the “pharmacy of the world”, resolve the friction between pharmaceutical patents and access to affordable medicines without putting off foreign investors? The vitriolic and polarising debate surrounding these questions has got a fresh lease of life following US President Barack Obama’s landmark three-day visit to India this week.
While Indian and American business moguls are bullish about the future, Indian generic drug-makers as well as health activists within and outside India are deeply anxious about the shape of things to come
At the World Health Organization Executive Board today, a group of countries tabled a proposal to extend the WHO plan of action on public health, innovation and intellectual property until 2022. Yesterday, the Executive Board took note of the Global Vaccine Action Plan while some countries remarked on issues of affordability and accessibility. And today, one of the key discussions of the week - on the engagement of WHO with lobbyists, donors, and other interested non-governmental parties - has begun.
Today's rejection by the Patent Office Controller of India of a patent application by Gilead company for a key drug against hepatitis C is being hailed by advocates as a path to dramatically lower costs of treatment for the disease. Hepatitis C has been noteworthy for exorbitantly priced medicines over the past year. A look at the decision shows that a provision in India's law continues to stop patent applications if they fail to show sufficient novelty and inventive step - and are subject to opposition.
The World Health Organization today optimistically announced progress in the search for efficient vaccines to fight the Ebola virus. Tests conducted so far show acceptable safety profiles, and public-private vaccine alliance Gavi has committed to fund Ebola vaccines.
The population in Uganda has been growing rapidly. The country now has 35 million people. In order to provide quality services to its citizens and to improve the national competitiveness through administration innovation, the government has adopted free and open source software as the preferred mode of operation for electronic government (e-government) services and platforms.